Navigation Links
Beckman Coulter Announces Second Quarter 2008 Results
Date:7/25/2008

2008 2007

GAAP operating income $142.3 $130.3

Reconciling items*:

Restructuring expenses (a) 5.4 10.5

HCV sublicense (b) 12.0 -

Fair market value inventory adjustment (d) 1.0 -

Rental tax dispute (e) - 1.6

Adjusted operating income $160.7 $142.4

GAAP operating margin 9.3% 10.0%

Impact of adjustments 1.2% 0.9%

Adjusted operating margin 10.5% 10.9%

*See accompanying Non-GAAP Financial Measures section for description of Non-GAAP adjustments

BECKMAN COULTER, INC.

RECONCILIATION OF GAAP NET EARNINGS TO ADJUSTED NET EARNINGS

(in millions, except amounts per share)

(unaudited)

Three Months Ended June 30,

2008 2007

Per Diluted Per Diluted

Amount Share Amount Share

GAAP net earnings $47.8 $0.74 $69.4 $1.09

Reconciling items*:

Restructuring expenses (a) 4.7 0.07 3.6 0.06

HCV sublicense (b) 12.0 0.19 - -

Miami vacant land sale (c) (1.2) (0.02) - -

Rental tax dispute (e) - - 2.4 0.04

Biosite break-up fee (f) - - (40.6) (0.64)

Adjustment for income taxes (5.9) (0.09) 13.0 0.20

Adjusted net earnings $57.4
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Beckman Coulter Announces Second Quarter 2008 Earnings to be Released on Friday, July 25, 2008, Before Market Opens
2. Upcoming Beckman Coulter Investor Events Second Half of 2008
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Beckman Coulter Announces First Quarter 2008 Results
5. Beckman Coulter Acquires Rights to Hepatitis C Virus
6. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
7. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
8. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
9. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
10. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
11. Beckman Coulter to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)... of durable pain palliation as a primary ... Milestone achievement results in release of es.../ OncoGenex,Pharmaceuticals...cluded a,meeting with the U.S. Food and Drug Admin...DA agreed that "durable pain palliation is an,acce...
(Date:10/13/2008).../Xinhua-- Pharmaxis,Ltd (AX...008 Quarterly,Report to Shareholders on the aftern...ill host an investor teleconference the following ...questions., The teleconference will be on Thursda... October at 5.30pm U.S. East Coast, 2.30pm U.S. We...
(Date:10/12/2008)...a., Oct. 12 /- Mentice, Inc., a,leadi...based medical,simulation systems and Education Man...l skills training and evaluation software solution...ular Therapeutics symposium in,Washington D.C., an...nticeSIM(TM) as a standard option to its flagship ...
(Date:10/10/2008)...wire/ -- CorMatrix Cardiovascular, Inc., an,Atlant...ring unique,extracellular matrix (ECM(TM)) biomate...y to repair damaged cardiovascular tissue, today a...tific Officer, will present data,on the company,s ...ranscatheter Cardiovascular Therapeutics (TCT) 200...
Breaking Biology Technology:OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011 2OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011 3OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011 4Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 2Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 3CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C. 2
...he business section of Sunday,s San Jose Mercury N...ff 35% ." , ,After several quarters of increasing ...illion into new businesses last quarter, down a th...ding to the MoneyTree Survey conducted by Pricewat...National Venture Capital Association. While a 35% ...
...dison, Wis. Governor Jim Doyle announced today o...r the state to maintain its leadership in the fiel...l research. The governor said that almost $750 mil...eral years, and he outlined a series of investment...ry on the UW-Madison campus. , Read the latest...
...he other day I went to a lecture on angel investin...ience raised his hand. He wanted to know whether t...s from Fond du Lac to Green Bay had enough entrep...nvestors. , ,When I heard this, I realized that th...nsins perception of itself. A number of Wisconsin-...
...or years, our firm has been touting the Bureau of ...oyees will leave the workforce for every new one e...e of ten million employees. , ,In an election cycl...ff-shoring is becoming de rigueur, these numbers s...st common arguments I hear refuting BLS statistics...
Other Biology Technology:Start-ups grow up 2Start-ups grow up 3Wisconsins governor unveils $750 million investment for stem cell and health research 2Wisconsin entrepreneurs need to self-promote like coastal rivals 2Wisconsin entrepreneurs need to self-promote like coastal rivals 3Wisconsin entrepreneurs need to self-promote like coastal rivals 4Wisconsin entrepreneurs need to self-promote like coastal rivals 5Wisconsin entrepreneurs need to self-promote like coastal rivals 6Talent shortage? Cmon. 2
(Date:10/10/2008)... in German . , DNA, the molecule that acts as...f life, is highly resistant against alteration by ... for its photostability presents some puzzling pro... four chemical bases that make up the DNA molecule... showing that DNA strands differ in their light se...
(Date:10/9/2008).... 9 /PRNewswire-FirstCall/ -- Synaptics(R),Incorpo...an interface,solutions for mobile computing, commu...day that it will report financial results for the ...23, 2008 after the close of market. The,company wi...ts and,investors at 2:00 p.m. PT (5:00 p.m. ET) du...
(Date:10/9/2008)...ed life,s ability to respond? Biodiversity in a Wa...f the journal, Science , illustrates that cross-d...ropical Research Institute in Panama clearly infor...region of rainforest and coral reefs, the tropics ...rming. Some disagree, arguing that tropical organi...
(Date:10/9/2008)...years, the number of patients with compromised imm...tients such as these require a unique set of healt...thing from the etiology and degree of immune suppr...tus. A new text from ASM Press, Diagnostic Microbi...ide range of approaches and challenges to infectio...
Breaking Biology News(10 mins):Can genetic information be controlled by light? 2Synaptics to Report First Quarter Results on October 23 2Smithsonian perspective: Biodiversity in a warmer world 2Text focuses on diagnosing infections in immunocompromised patients 2Threshold for bowel surgery may be too high warn experts 5076 1Threshold for bowel surgery may be too high warn experts 5076 2MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 1MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 2MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 3MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 5073 4Anesiva Announces Upcoming Webcasts and Conference Participation 5068 1Anesiva Announces Upcoming Webcasts and Conference Participation 5068 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 1King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 3King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 4King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 5King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 6
...trospective study in the Canadian Medical Associat...ularly boys, are about twice as likely as the tota...m an injury. , Brison and colleagues collected and...ries to young children to determine rates, identif...ms and ranches. They found that children 1? years ...
...e compounds could be a key component for cheaper, ...a Richards in Chemistry & Industry magazine. ,...each year, of which nearly 2,700 die, according to...ut is unsuitable for most patients, and liver tumo...an Cancer Society estimates that 18,510 new cases ...
...ers have found that the neurotransmitter serotonin...promote lasting, quality sleep in an animal model ...ntral to the lives of most animals, the proper reg... , The findings are reported by Quan Yuan, Willia...nnsylvania, and appear in the June 6th issue of Cu...
...e lovers, beware. Each year 20 percent of the caca...o plant diseases, but even greater losses would oc...eases are the most important constraints to cacao ...d,s confectionary trades," said Randy Ploetz, plan..., Homestead, FL. Currently, 4 million metric tons ...
Other Biology News:
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies.
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)
PP2B-Abeta (C-20)
... intensely fluorescent and highly photostable Fluo...se in a variety of applications requiring probes t...otein- and other macromolecule-labeled microsphere...bind to non-target surfaces in some applications. ...
Biology Products: